{
  "first_published_at": "2014-02-12", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON377646", 
  "title": "Abraxane (paclitaxel, formulated as albumin-bound nanoparticles): potential presence of strands in intravenous infusion bag—if visible, filtration advised", 
  "tags": "{\"parsed_therapeutic\": [\"cancer\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Cancer\"]}", 
  "_document_number": 37, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/dose_icon.png", 
  "therapeutic_area": [
    "cancer"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Abraxane (paclitaxel, formulated as albumin-bound nanoparticles): potential presence of strands in intravenous infusion bag&#8212;if visible, filtration advised</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: February 2014</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--There have been reports from Europe of thin, translucent or white-to-yellow proteinaceous strands (1&#8211;2 mm in length) being observed during visual inspection of bags of reconstituted paclitaxel suspension for intravenous infusion.There is no evidence of an increased risk of any adverse effect in patients treated with Abraxane containing strands. However, as a precaution we are advising that Abraxane with visible strands should be filtered-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Abraxane (paclitaxel, formulated as albumin-bound nanoparticles) is a treatment for metastatic breast cancer in patients who have not responded to first-line treatment, or for whom standard anthracycline-containing therapy is not indicated.</p>\n\n<p>There have been reports from Europe of thin, translucent or white-to-yellow proteinaceous strands (1&#8211;2 mm in length) being observed during visual inspection of bags of reconstituted paclitaxel suspension for intravenous infusion. The cause of these strands is thought to be an interaction between albumin and silicone oil lubricant within medical devices such as syringes and locks of intravenous bags. There is no evidence of an increased risk of any adverse effect in patients treated with Abraxane containing strands. However, as a precaution we are advising that Abraxane with visible strands should be filtered as outlined below.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>As a precaution, Abraxane suspension should be inspected visually using standard procedure for presence of particulate matter or discolouration in the infusion bag before administration. The suspension should appear milky and homogenous without visible precipitates</li>\n\n<li>If strands are visible in the bag, administer Abraxane through an infusion set incorporating a 15 micrometre filter. This filter removes strands and does not change the physical or chemical properties of the reconstituted product. If strands are present and a filter is not available, discard the product</li>\n\n<li>Suspected adverse reactions or the presence of visible strands in Abraxane can be reported to us on a Yellow Card (<a href=\"http://www.mhra.gov.uk/yellowcard\">www.mhra.gov.uk/yellowcard</a>)</li>\n</ul>\n</div>\n\n<p><strong>Further information</strong></p>\n\n<p>See<a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON370026\" target=\"_blank\"> letter sent to healthcare professionals</a>, January 2014</p>\n\n<p><em>Article citation: Drug Safety Update volume 7 issue 7, February 2014: S1.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Abraxane (paclitaxel, formulated as albumin-bound nanoparticles) is a treatment for metastatic breast cancer in patients who have not responded to first-line treatment, or for whom standard anthracycline-containing therapy is not indicated.</p>\n\n<p>There have been reports from Europe of thin, translucent or white-to-yellow proteinaceous strands (1&#8211;2 mm in length) being observed during visual inspection of bags of reconstituted paclitaxel suspension for intravenous infusion. The cause of these strands is thought to be an interaction between albumin and silicone oil lubricant within medical devices such as syringes and locks of intravenous bags. There is no evidence of an increased risk of any adverse effect in patients treated with Abraxane containing strands. However, as a precaution we are advising that Abraxane with visible strands should be filtered as outlined below.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>As a precaution, Abraxane suspension should be inspected visually using standard procedure for presence of particulate matter or discolouration in the infusion bag before administration. The suspension should appear milky and homogenous without visible precipitates</li>\n\n<li>If strands are visible in the bag, administer Abraxane through an infusion set incorporating a 15 micrometre filter. This filter removes strands and does not change the physical or chemical properties of the reconstituted product. If strands are present and a filter is not available, discard the product</li>\n\n<li>Suspected adverse reactions or the presence of visible strands in Abraxane can be reported to us on a Yellow Card (<a href=\"http://www.mhra.gov.uk/yellowcard\">www.mhra.gov.uk/yellowcard</a>)</li>\n</ul>\n</div>\n\n<p><strong>Further information</strong></p>\n\n<p>See<a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON370026\" target=\"_blank\">letter sent to healthcare professionals</a>, January 2014</p>\n\n<p><em>Article citation: Drug Safety Update volume 7 issue 7, February 2014: S1.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2014-02-01", 
  "date_last_modified": "2014-02-13", 
  "_assets": [], 
  "_item_id": 37, 
  "summary": "", 
  "body": "Article date: February 2014\n\nAbraxane (paclitaxel, formulated as albumin-bound nanoparticles) is a treatment for metastatic breast cancer in patients who have not responded to first-line treatment, or for whom standard anthracycline-containing therapy is not indicated.\n\nThere have been reports from Europe of thin, translucent or white-to-yellow proteinaceous strands (1–2 mm in length) being observed during visual inspection of bags of reconstituted paclitaxel suspension for intravenous infusion. The cause of these strands is thought to be an interaction between albumin and silicone oil lubricant within medical devices such as syringes and locks of intravenous bags. There is no evidence of an increased risk of any adverse effect in patients treated with Abraxane containing strands. However, as a precaution we are advising that Abraxane with visible strands should be filtered as outlined below.\n\nAdvice for healthcare professionals:  \n  \n  * As a precaution, Abraxane suspension should be inspected visually using standard procedure for presence of particulate matter or discolouration in the infusion bag before administration. The suspension should appear milky and homogenous without visible precipitates  \n  * If strands are visible in the bag, administer Abraxane through an infusion set incorporating a 15 micrometre filter. This filter removes strands and does not change the physical or chemical properties of the reconstituted product. If strands are present and a filter is not available, discard the product  \n  * Suspected adverse reactions or the presence of visible strands in Abraxane can be reported to us on a Yellow Card ([www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard))  \n  \nFurther information\n\nSee[letter sent to healthcare professionals](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON370026), January 2014\n\nArticle citation: Drug Safety Update volume 7 issue 7, February 2014: S1.\n"
}